2024
Prediction of gastrointestinal symptoms trajectories using omega-3 and inflammatory biomarkers in early-stage breast cancer patients receiving chemotherapy
Arcos D, Ng D, Ke Y, Toh Y, Chan A. Prediction of gastrointestinal symptoms trajectories using omega-3 and inflammatory biomarkers in early-stage breast cancer patients receiving chemotherapy. Supportive Care In Cancer 2024, 32: 76. PMID: 38170327, PMCID: PMC10764400, DOI: 10.1007/s00520-023-08274-5.Peer-Reviewed Original ResearchConceptsEarly-stage breast cancer patientsBreast cancer patientsTreatment of Cancer Quality of Life QuestionnaireCancer Quality of Life QuestionnaireCancer patientsFemale breast cancer patientsQuality of Life QuestionnaireEORTC QLQ-C30European Organisation for ResearchProspective cohort studyQuality of lifeSymptom progressionGI symptomsQLQ-C30Life QuestionnaireSecondary analysisSymptom trajectoriesCohort studyResultsThe analysisInferential statisticsBaseline inflammatory markersAppetite lossInflammatory biomarkersSymptomsBaseline
2022
Cognitive impairment in adolescent and young adult cancer patients: Pre‐treatment findings of a longitudinal study
Chan A, Cheng I, Wang C, Tan C, Toh Y, Ng D, Koh Y, Zhou H, Foo K, Chan R, Ho H, Chew L, Farid M, Tannock I. Cognitive impairment in adolescent and young adult cancer patients: Pre‐treatment findings of a longitudinal study. Cancer Medicine 2022, 12: 4821-4831. PMID: 36221816, PMCID: PMC9972136, DOI: 10.1002/cam4.5295.Peer-Reviewed Original ResearchConceptsHealthy controlsSystemic therapyInitiation of systemic therapyCancer-related cognitive impairmentBaseline inflammatory markersMulticenter cohort studyPre-treatment findingsCognitive functionCognitive impairmentInflammatory markersRare incidenceCohort studyAdult cancer patientsCancer patientsPrimary outcomeEvaluation of cognitive functionSecondary outcomesRisk factorsCognitive testsQuality of lifeDeterioration of cognitive functionEarly rehabilitationCancer diagnosisPredicting cognitive functionTherapy
2019
Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel.
Thomas M, James S, Becker R, Himmelmann A, Katus H, Cannon C, Steg P, Siegbahn A, Lakic T, Storey R, Wallentin L. Prognostic impact of baseline inflammatory markers in patients with acute coronary syndromes treated with ticagrelor and clopidogrel. European Heart Journal Acute Cardiovascular Care 2019 PMID: 33609104, DOI: 10.1177/2048872619878075.Peer-Reviewed Original ResearchWhite blood cell countBaseline inflammatory markersTicagrelor compared to clopidogrelBlood cell countInflammatory markersC-reactive proteinAcute coronary syndromePrimary endpointCardiovascular deathCell countNeutrophil countClinical outcomesAcute coronary syndrome treated with ticagrelorCoronary syndromeCardiovascular benefitsN-terminal pro-brain-type natriuretic peptideInterleukin-6Increased risk of adverse cardiovascular eventsQuartile of white blood cell countComposite of cardiovascular deathAssociated with clinical outcomesRisk of adverse cardiovascular eventsLevels of inflammatory markersAcute coronary syndrome patientsPLATO study
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply